Vericel (VCEL) Shares Outstanding (Weighted Average) (2010 - 2026)
Vericel's (VCEL) quarterly Shares Outstanding (Weighted Average) came in at $50.8 million in Q1 2026, up 1.74% year-on-year from $49.9 million in Q1 2025, and up 0.86% quarter-over-quarter from $50.3 million in Q4 2025.
Vericel (VCEL) Shares Outstanding (Weighted Average) (2010 - 2026) Analysis & Trends
Vericel has disclosed Shares Outstanding (Weighted Average) across 17 years of filings, most recently posting $50.8 million for Q1 2026.
- Shares Outstanding (Weighted Average) for Q1 2026 came in at $50.8 million, up 1.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.8 million (up 1.74% YoY), and the FY2025 annual result was $50.3 million, up 3.05% from the prior year.
- Shares Outstanding (Weighted Average) came in at $50.8 million for Q1 2026 at Vericel, up from $50.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $50.8 million in Q1 2026 to a low of $47.0 million in Q1 2022.
- The 5-year median for Shares Outstanding (Weighted Average) is $48.1 million (2024), against an average of $48.5 million.
- Across the five-year window, Shares Outstanding (Weighted Average) gained 0.77% in 2023 and advanced 4.04% in 2025, its largest moves.
- Vericel's Shares Outstanding (Weighted Average) stood at $47.1 million in 2022, then increased by 0.98% to $47.6 million in 2023, then rose by 2.64% to $48.8 million in 2024, then climbed by 3.05% to $50.3 million in 2025, then increased by 0.86% to $50.8 million in 2026.
- The last three Shares Outstanding (Weighted Average) figures came in at $50.8 million (Q1 2026), $50.3 million (Q4 2025), and $50.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | 50.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 50.77 Mn |
| Dec 31, 2025 | 50.34 Mn |
| Sep 30, 2025 | 50.49 Mn |
| Jun 30, 2025 | 50.37 Mn |
| Mar 31, 2025 | 49.91 Mn |
| Dec 31, 2024 | 48.85 Mn |
| Sep 30, 2024 | 48.64 Mn |
| Jun 30, 2024 | 48.41 Mn |
| Mar 31, 2024 | 48.14 Mn |
| Dec 31, 2023 | 47.59 Mn |
| Sep 30, 2023 | 47.65 Mn |
| Jun 30, 2023 | 47.48 Mn |
| Mar 31, 2023 | 47.39 Mn |
| Dec 31, 2022 | 47.13 Mn |
| Sep 30, 2022 | 47.10 Mn |
| Jun 30, 2022 | 47.12 Mn |
| Mar 31, 2022 | 46.99 Mn |
| Dec 31, 2021 | 46.47 Mn |
| Sep 30, 2021 | 46.67 Mn |
| Jun 30, 2021 | 46.20 Mn |